You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 17, 2024

Details for New Drug Application (NDA): 017442


✉ Email this page to a colleague

« Back to Dashboard


NDA 017442 describes MINIPRESS, which is a drug marketed by Pfizer and is included in two NDAs. It is available from four suppliers. Additional details are available on the MINIPRESS profile page.

The generic ingredient in MINIPRESS is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.
Summary for 017442
Tradename:MINIPRESS
Applicant:Pfizer
Ingredient:prazosin hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 017442
Mechanism of ActionAdrenergic alpha-Antagonists
Medical Subject Heading (MeSH) Categories for 017442
Suppliers and Packaging for NDA: 017442
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442 NDA Pfizer Laboratories Div Pfizer Inc 0069-4310 0069-4310-71 250 CAPSULE in 1 BOTTLE (0069-4310-71)
MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442 NDA Pfizer Laboratories Div Pfizer Inc 0069-4370 0069-4370-71 250 CAPSULE in 1 BOTTLE (0069-4370-71)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 5MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 1MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 2MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Expired US Patents for NDA 017442

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-002 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-002 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-003 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-002 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-001 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-001 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-003 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.